Cumambrin B Alleviates Acute Lung Injury In Vivo and Attenuates NF‐κB/MAPK‐Mediated Inflammation and Oxidative Stress by Regulating the Accumulation of ROS In Vitro

作者：Qianqian Ren, Yuemei Que, Xiaoran Min, W. Mu, Dan‐dan Ruan, Peixing Wang, Xiling Dai, Jianguo Cao, Yanzi Yang, Guozheng Huang · 发表于：Archiv der Pharmazie · 年份：2025 · DOI：10.1002/ardp.70137 · 被引用次数：3 · 研究领域：Medicinal Plants and Bioactive Compounds、Natural Compounds in Disease Treatment、Andrographolide Research and Applications

Acute lung injury (ALI) represents a critical medical issue typified by serious respiratory dysfunction, which frequently progresses to acute respiratory distress syndrome (ARDS), a condition linked to elevated rates of morbidity and mortality. In the present research, cumambrin B (CB), a sesquiterpene lactone extracted from Ajania fruticulosa (Ledeb.) Poljak was systematically examined, focusing on its potential anti-inflammatory molecular mechanism and therapeutic efficacy in ALI models. In vitro, lipopolysaccharide (LPS) was demonstrated to activate nuclear factor kappa B (NF-κB) or mitogen-activated protein kinase (MAPK) pathways in RAW264.7 macrophages, triggering protein phosphorylation. Conversely, treatment with CB selectively suppressed phosphorylation events and inhibited the initiation of these pathways. In vivo, CB ameliorated LPS-induced pathological alterations, including alveolar wall thickening and parenchymal structural disruption. Further analysis demonstrated that CB pretreatment alleviated LPS-induced pulmonary edema, as substantiated by a reduced pulmonary wet-to-dry ratio, and mitigated lung inflammation, indicated by decreased interleukin 6 (IL-6) mRNA expression in lung tissue, lower IL-6 levels, reduced leukocyte counts, and diminished bronchoalveolar lavage fluid (BALF) content of total protein in mice. Conclusively, our research indicates that CB exhibits potential as a viable pharmaceutical agent for managing inflammatory conditions, such as ALI.